Mergers and acquisitions have been a hot topic throughout the drug industry lately, as companies face slowing sales and rising costs. In fact, deals worth $128 billion have been announced in the sector so far this year, according to Dealogic. This is the highest total since 2009.
As of late, Pfizer Inc.’s $100 billion bid for AstraZeneca is the largest and most recent in a series of proposed big pharma mergers. Pfizer has a new approach to AstraZeneca PLC regarding a takeover valued at almost $100 billion, but the U.K.-listed pharmaceutical firm declined to discuss further.